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ABSTRACT
Objective The term hepatoid adenocarcinoma (HAC) of the stomach was introduced three decades
ago with the observation of high serum a-fetoprotein (AFP) levels in some gastric adenocarcinoma
patients. This very rare gastric cancer patient subgroup is likely frequently misdiagnosed.
Material Two patients who were recently diagnosed with HAC of the stomach at our institution are
presented. We also performed a structured literature search and reviewed pertinent articles to
provide knowledge to improve the proper identification, diagnosis and management of patients
with gastric HAC. Results HAC is a rare subgroup of gastric carcinoma with poor prognosis. Clinical
management of this population may be challenging. The scientific literature is largely based on
very small patient series or case reports, and the evidence for proper decision making and
management is considered weak. Conclusion All physicians involved in the diagnosis and
treatment of patients with gastric cancer should pay attention to this rare subgroup to improve
identification.
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Although the term hepatoid adenocarcinoma (HAC) of the
stomach was introduced in 1985 by Ishikura et al., with the
observation of high serum a-fetoprotein (AFP) levels in
seven patients with gastric adenocarcinoma,[1,2] an AFP-
producing gastric tumour was first reported by Bourreille
et al.[3] in 1970. HAC may also originate from other
gastrointestinal localisations,[4,5] including the pan-
creas.[6,7] Moreover, this extrahepatic hepatoid cancer
type has also been diagnosed in the ovary,[8] uterus,[9]
lungs,[10,11] and several other organs.[4,12] The scientific
literature, however, is mostly based on case reports or very
small patient series.[1,13–17]
Although previous reports have suggested that the
incidence of gastric HAC is between 0.38% and 0.78%,
[15,18] recent reports from Korea [14] and China [19]
have provided figures of 0.17% and 0.36%, respectively.
HAC is considered an aggressive type of gastric adeno-
carcinoma with a detrimental prognosis.[14,19–22] Thus,
challenges remain both with regard to the appropriate
identification and diagnosis of this rare entity and
concerning effective treatments to improve this
unfavourable prognosis.
Based on a review of the available literature and the
presentation of two patients who were recently treated
at our institution, some relevant clinical aspects are
addressed to bring to the attention of both involved
clinicians (i.e. gastroenterologists, gastroenterologic sur-
geons, and oncologists) and pathologists and radiolo-
gists: the importance of the correct subclassification of
gastric cancer and a better understanding of the
characteristics of each subtype to improve early diag-
nosis and enable appropriate treatment.[23,24]
Material and methods
Literature search
We searched the PubMed and Ovid Medline databases
for articles published between January 2005 and June
2015 using combinations of the terms ‘hepatoid adeno-
carcinoma’, ‘stomach’, ‘gastric’, ‘gastric cancer’, ‘adeno-
carcinoma’, ‘alpha-fetoprotein’, ‘treatment’, ‘prognosis’,
and ‘surgery’. Earlier seminal and highly regarded
publications were considered. References were selected
based on the information provided, with an emphasis on
patient series and reports that expanded diagnostic
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tools, improved identification or were found to substan-
tiate fundamental knowledge concerning this condition.
Patients
Case report #1
An otherwise healthy male (49 years of age), with a two-
year history of increasing fatigue, epigastric discom-
fort, nausea, anaemia, and slightly increasing serum
a-fetoprotein (AFP) levels for the last 12 months, was
extensively examined over the past year at other
hospitals by gastroscopy, coloscopy, liver imaging,
including magnetic resonance (MR) imaging, and posi-
tron emission tomography–computer tomography (PET-
CT) without any significant findings.
Due to anaemia and vague epigastric pains, he was
then referred to our hospital where a repeat gastroscopy
revealed a large and soft tumour in the proximal part of
the stomach (Figure 1). Serum AFP levels were extremely
elevated at 21,045 kU/L (normal,560 kU/L) (Figure 2).
Except for a slightly elevated serum chromogranin A
(CgA) value of 8.8 nmol/L (normal56.0 nmol/L), other
tumour markers, including carcinoembryonic antigen
(CEA), and carbohydrate antigen 19-9 (CA 19-9),
were completely normal. Abdominal computer tomog-
raphy (CT) revealed a large gastric tumour (size:
63 77 86 mm) with a suspicious tumour infiltration
of the diaphragm, left liver, and spleen (Figure 3), but
without distant metastases. Histology of the endoscopic
biopsy revealed a pattern consistent with gastric adeno-
carcinoma of the hepatoid subtype (Figure 4). Upon
extended immunohistochemical examination (IHC),
strong AFP staining was observed (Figure 4), but there
was no staining of synaptophysin, chromogranin A
(CgA), CD 56, or HER2.
The patient consented to surgical treatment, which
included a total gastrectomy with a wedge resection of
the liver and a distal pancreas resection including a
splenectomy. In addition, a partial resection of the left
diaphragm and a limited resection of the inferior lobe of
the lung were performed. The tumour diameter was
Figure 3. Pt #1: Coronal multi detector computer
tomography(MDCT) shows the gastric tumour (T) in the left
hypochondrium with infiltration of the left hemidiaphragma
(stapled arrow) and the greater curvature (arrow) of the
stomach.
Figure 1. Pt #1: Male 48 years of age. Endoscopic view of the
gastric tumour located in the fundus.
Figure 2. Time trends of the AFP levels in Pt #1 during the
trajectory of his disease.
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80 mm, with minimal microscopic infiltration into the
liver, diaphragm, and lung, but without evidence of
infiltration into the spleen or pancreas. Specimen
margins were microscopically tumour free (R0 resection).
The tumour was classified (WHO 2010) as pT4bN1M0.
Additional IHC of the resected tumour did not show any
staining for CD117 (c-kit), and no epidermal growth
factor receptor (EGFR) mutation was found with a
molecular genetic test.
The post-operative course was complicated by small
bowel obstruction that prompted a re-laparotomy on
the eighth post-operative day, with a re-suture (add-
itionally enforced by biological mesh) of the partly
disrupted left diaphragm suture line, which had caused
an obstruction of a short wedged-in segment of the
small bowel. Thereafter, no other specific post-operative
surgical complications were encountered, but the
patient recovered very slowly after being discharged
from the hospital, suffering subjectively from extensive
fatigue, which he had also experienced over the last 6 to
9 months pre-operatively, and regaining a normal diet
was a challenge. Adjuvant chemotherapy was con-
sidered, but due to the patient’s impaired clinical
condition (ECOG 3) and his own preference, adjuvant
treatment was not offered.
At follow-up 3 months after surgery, lung CT revealed
small nodules in the upper left lobe, and abdominal CT
demonstrated a metastatic liver lesion of 23 mm in
diameter, located in the right hemiliver far away from
the wedge resection line. Although his general physical
status had improved slightly, he was hardly fit for any
palliative chemotherapy, which he also refused. The
patient died 9 months after surgery for a confirmed
hepatoid adenocarcinoma of the stomach.
Case report #2
An 81-year-old female with weight loss for two months,
was admitted with haematemesis. Gastroscopy revealed
a large suspicious tumour of the distal stomach. Further
work-up including a CT confirmed a large and diffuse
gastric tumour, with tumour growth into the surround-
ing tissues and enlarged mesenteric lymph nodes (LN) in
addition to enlarged LN of the lesser curve (Figure 5). No
liver or lung metastases were observed. Tumour
markers, including CEA and CA-125, were normal. A
significantly elevated serum AFP value of 14,414 kU/L
(normal,560 kU/L) was encountered. Histology con-
cluded primarily with an adenocarcinoma of the stom-
ach. Based on the increased AFP levels, additional IHC
examination of the gastric biopsy was done. A strong
staining for AFP was shown, but in addition a few
scattered cells (55%) stained positive both for synapto-
physin and for chromogranin A(CgA). This pattern,
Figure 4. (A) Histopathology of hepatoid carcinoma in the gastric mucosal primary lesion The tumour comprised a mixture of
pseudoglandular and hepatoid components. Note the normal glandular structure (arrows) (haematoxylin and eosin staining; original
magnification,400). (B) Immunohistochemical staining showing intracytoplasmic positivity for AFP (dark brown). Note the non-
staining normal glandular structure (arrows) (original magnification, x400).
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however, did not allow for the diagnosis of a neuroen-
docrine tumour. Thus, morphologically the diagnosis of
a gastric HAC was made.
Due to the locally advanced tumour and the general
health condition of the patient (ECOG 3; ASA 4) as well
as her own strong preferences, tumour-directed therapy
(i.e. surgery or systemic chemotherapy) was not
employed. During the course of the disease, moderate
signs of delayed gastric emptying were encountered,
and a follow-up CT with findings of a significant tumour
growth was performed 6 months after the primary
diagnoses. In addition, serum AFP levels of 166,000 kU/L
were found, which was a 10-fold increase over the 6
months since the time of diagnosis. After a few short
hospital admissions for transfusions and supportive care,
the patient eventually died 7 months after the diagnosis
of a gastric HAC was made.
Results
The frequency of HAC is extremely low, and the scientific
literature comprises mostly case reports or very small
patient series. Su et al. reviewed the literature on
hepatoid adenocarcinoma between 2001 and 2011 and
recently presented a summary on 217 patients, including
182 (83.9%) patients with hepatoid adenocarcinoma
located in the stomach.[4] To add data obtained in more
recent years, we have collected pertinent information
from recent publications that included a minimum of
10 patients,[14,19,20,23,25] and relevant information is
presented in Table 1. In their review of 26 patients, Baek
et al.[14] observed the predominance of males, the
presence of local advanced or metastatic disease in half
of the patients at the time of diagnosis, and a Bormann
type-III cancer [26] most frequently found with gastros-
copy. A tumour located at the distal area of the stomach
(i.e. antrum) was commonly encountered. Similar clinical
patterns were in essence reported by two studies from
China, one earlier [15] and one more recent,[26] with 31
and 20 patients, respectively. Of note is the detrimental
prognosis, with an overall survival of less than a year in a
large proportion of the patients. Based on the available
heterogeneous and limited literature comprising case
reports, reliable figures for the true incidence, clinical
characteristics, and treatment outcomes are not easily
provided.
Discussion
A proper identification of patients with gastric HAC
remains a challenge. Reliable clinical patterns and clues
are lacking.
Imaging does not provide features specific for gastric
HAC. Ren et al.[13] reported six cases with extensively
thickened gastric walls by heterogeneous contrast
enhancement and a polypoid mass identified at CT.
These observations are generally supported by
others, who also emphasise the common findings of
Figure 5. Pt # 2: Female 81 years of age. (A) Axial MDCT at the time of diagnosis showing the gastric tumour (T) located in the antrum,
with lymph nodes (LN) at the lesser curvature. (B) Five months after primary diagnosis: disease progression with liver metastasis (M),
tumour and lymph node growth (T) along the lesser curvature, ascites (A) and thrombus in portal veins (white arrow).
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lymphadenopathy and distant metastases in these
groups of patients.[16,27] Magnetic resonance imaging
(MRI) may help provide a more specific diagnosis, as
suggested recently.[28] In contrast to our male patient
without any uptake on PET-CT, others have reported
positive findings in patients with HAC.[5,29]
Morphologically, hepatoid adenocarcinoma of the
stomach is a type of extrahepatic carcinoma with a
complex histological picture, including enteroblastic and
hepatic differentiation.[30] However, its similarity to
hepatocellular carcinoma (HCC) of the liver is evident.
As originally described by Ishikura et al.,[1] these gastric
carcinomas comprise both adenocarcinomatous and
hepatocellular differentiations. The adenocarcinomatous
and hepatoid areas were often intermingled with each
other, and an extensive venous involvement by tumour
cells was noted.[1] Moreover, the tumour cells contain
various serum proteins, including AFP, alpha-1 antitryp-
sin (AAT), alpha-1 antichymotrypsin (ACT), albumin, and
prealbumin, in their cytoplasm, which can be shown by
positive immunohistochemical staining. Because HAC
and HCC cannot be differentiated on the basis of
morphology alone, differences in immunehistochemical
reaction patterns may enable the correct diagnosis. As
shown in several reports, immune staining for CK7, CK8,
CK18, CK19, CK20, alpha-fetoprotein (AFP), p-CEA, and
HepPar1 revealed that hepatoid areas of both primary
and metastatic HAC have a specific immune profile that
is distinct to this entity.[31–34] This should help the
pathologist once a diagnosis of HAC has been
considered.
AFP is a foetal serum protein produced by foetal and
yolk sac cells and by some foetal gastrointestinal cells.
After birth, the level of the protein in the serum rapidly
decreases. AFP as a tumour marker is not by itself
diagnostic, only suggestive. Whereas elevated levels
of AFP are mainly associated with the occurrence of
a hepatocellular carcinoma (HCC), a number of other
tumours including non-seminomatous germ cell
tumours and endodermal sinus tumours (i.e. york sac
carcinoma) can give rise to increased AFP levels.[5,6,35–
38] If AFP is measured, the interpretation of a raised AFP
level may not be straightforward, which is particularly
important in endemic areas with a high incidence of
chronic hepatitis B and C and HCC. Although most
patients (at least 80%) with gastric HAC will have
elevated serum AFP levels, this is not the case in all
patients with gastric HAC. [4] As observed in our male
patient and as observed by others, a resection of the
tumour causes a decrease in AFP levels, which eventually
increases again when distant metastases are evident.
Thus, hepatoid adenocarcinoma (HAC) is a rare but
important specific type of extrahepatic adenocarcinoma
that should be distinguished from HCC.[4] Although the
stomach is by far the most prevalent location, other
gastrointestinal locations [39–41] and the genitals have
been reported.[4,8,37]
The so-called composite or mixed tumour with
hepatoid and neuroendocrine differentiation in the
same gastric tumour has been reported,[42–44] which
has also been encountered in HAC tumours of other
locations (i.e. pancreas).[7,38] Still, the clinicopathologi-
cally importance and understanding of the composition
of a gastric HAC and a neuroendocrine cancer remains
uncertain.[43] As also shown in the tumour of our
patient #2, a very weak IHC staining (55% of the cells) for
CgA was encountered, although fare too weak to
support a diagnosis of a mixture with a HAC and a
neuroendocrine tumour in this case.
We have not been able to find any evidence for a
relationship between gastric HAC and known risk factors
for developing a common gastric adenocarcinoma, such
as H. pylori infection or chronic atrophic gastritis. Of note
is a reported substantial male predominance,[4,14] but it
remains to be shown if any specific factors can explain
this gender difference.
Recently, Vivekanandarajah et al.[21] claimed that
they were the first to report on a patient with AFP-
producing gastric adenocarcinoma without hepatic
metastases. Neither of our two patients had liver
metastases as demonstrated by imaging at the time of
diagnosis, and although advanced disease is common in
this particular subgroup of patients with gastric cancer,
recent reports have already shown that a proportion of
these patients are diagnosed with local disease.[4,20]
Although prognosis appears detrimental despite the
treatments employed, a number of patients have been
surgically treated. Our male patient had a locally
advanced disease, and radical surgery with free margins
was achieved. Nevertheless, an early recurrence and a
short survival were observed, which has also been
reported by others.[4,19,20] Adjuvant chemotherapy
treatments have been employed, but it remains to be
shown which drugs or combinations of drugs should be
used, and the evidence is weak based on the limited
clinical experience.[14,19,45] The same applies for
neoadjuvant chemotherapy [46,47] and palliative sys-
temic treatments,[48,49] which have been offered to a
small number of patients.
As already stated by Ishikura et al.[1] when they first
described this entity in 1986, the observed poor prog-
nosis may be attributed to the observed mixture of
adenocarcinomatous foci and hepatoid areas and to the
production of AFP and the presence of alpha-1
antitrypsin (AAT) and alpha-1 antichymotrypsin (ACT),
which have immunosuppressive and protease-inhibitory
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properties. The detrimental prognosis and the aggres-
sive biological behaviour of this gastric cancer subtype
may also be partly explained by the finding of a high
malignant potential (high proliferative activity, weak
apoptosis, and rich neovascularisation) in AFP-positive
gastric cancers compared with AFP-negative gastric
cancers.[50]
Likely, a number of gastric cancer patients with the
HAC subtype, whether it is AFP-producing or not, are
misdiagnosed.[23] The correct diagnosis of malignancy,
a precise classification of the tumour type and an
appropriate staging of the disease are all important
factors to provide suitable and individualised surgical or
oncologic treatment to improve prognosis and patient
care. This pathology was first described almost three
decades ago,[1,2] and since then, a number of reports
have been published, mostly in the context of case
reports and small patient series. Nevertheless, the
community of gastroenterologists, hepatologists,
endoscopists, gastrointestinal surgeons, pathologist,
radiologists, and oncologists should all bring this
disease to their attention to arrive at a correct diag-
nosis that may enable appropriate treatment to
improve patient care and the dismal prognosis of this
pathology.
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